Synergy Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel GI therapies. Since the company’s inception in 2008, we have pioneered discovery, research, and development efforts in the treatment of functional GI disorders, GI conditions, and inflammatory bowel disease. Our proprietary GI platform is based on uroguanylin, a naturally occurring human GI peptide that plays an important role in supporting normal bowel function.
420 Lexington Ave.
New York, New York 10170